Form 4: TherapeuticsMD Director Buys 8,400 Shares

TherapeuticsMD Director Tommy G. Thompson acquired 8,400 shares of common stock at $1.6703 per share in a pre-planned transaction.

Summary

• Tommy G. Thompson, a Director of TherapeuticsMD, Inc. (TXMD), purchased 8,400 shares of common stock.
• The transaction occurred on December 23, 2025, at a price of $1.6703 per share.
• Following this purchase, Mr. Thompson directly owns 23,179 shares and indirectly owns 14,312 shares through Thompson Family Investments, LLC.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.

Sentiment

Score: 8

Explanation: A director's purchase of company stock is a strong positive signal, indicating confidence in the company's future prospects and potentially undervalued stock. The transaction being pre-planned (Rule 10b5-1(c)) suggests a deliberate investment strategy.

Positives

• A director's purchase of company stock signals confidence in the company's future prospects.
• The acquisition of 8,400 shares at $1.6703 per share represents a direct investment by a key insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This transaction is specific to TherapeuticsMD and does not directly reflect broader industry trends, though it could influence investor sentiment towards the company within the pharmaceutical or biotech sector.

Related Party Transactions

• The indirect ownership of 14,312 shares through Thompson Family Investments, LLC, which is owned by Thompson Family Holdings, LLC, both ultimately owned by Mr. Thompson, represents a related party holding.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees could interpret the insider buying as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The purchase of company stock by a director, especially a significant amount like 8,400 shares, is a strong indicator of insider confidence. While the transaction was pre-planned under Rule 10b5-1(c), it still reflects a deliberate decision by a key insider to increase their stake, suggesting they believe the stock is undervalued or has strong future potential. This typically signals a positive outlook for the company's stock performance.

Keywords

TherapeuticsMD, TXMD, insider trading, Form 4, stock purchase, director, Tommy G. Thompson, equity acquisition, beneficial ownership